We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

BAX 855 Dose-Escalation Safety Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01599819
First Posted: May 16, 2012
Last Update Posted: October 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Baxter Innovations GmbH
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )
  Purpose
The objectives of this study are to assess the tolerability and safety after single dose treatments of BAX 855 in previously treated patients (PTPs) with severe hemophilia A, to determine the pharmacokinetic (PK) parameters of BAX 855 compared in crossover with ADVATE, and to evaluate the impact of anti-polyethylene glycol (PEG) antibodies on PK parameters.

Condition Intervention Phase
Hemophilia A Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method Biological: PEGylated Recombinant Factor VIII Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A

Resource links provided by NLM:


Further study details as provided by Shire ( Baxalta now part of Shire ):

Primary Outcome Measures:
  • Serious and non-serious AEs [ Time Frame: 4 weeks after infusion with BAX 855 and ADVATE ]

Enrollment: 19
Study Start Date: September 2011
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
Low dose of ADVATE followed by low dose of BAX 855
Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
Other Name: ADVATE
Biological: PEGylated Recombinant Factor VIII
1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
Other Name: BAX 855
Experimental: Cohort 2
High dose of ADVATE followed by high dose of BAX 855
Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
Other Name: ADVATE
Biological: PEGylated Recombinant Factor VIII
1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
Other Name: BAX 855

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject is male and is 18 to 65 years of age at the time of screening
  • The subject has severe hemophilia A (factor VIII level < 1%)
  • The subject was previously treated with plasma-derived factor VIII (FVIII) concentrates or recombinant FVIII for at least 150 exposure days (EDs)

Exclusion Criteria:

  • The subject has a detectable FVIII inhibitor at screening, with a titer >= 0.6 BU
  • The subject has a documented history of FVIII inhibitors with a titer >= 0.4 BU at any time prior to screening
  • The subject has a known hypersensitivity towards mouse or hamster proteins or to polyethylene glycol (PEG)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01599819


Locations
Bulgaria
Specialized Hospital for Active Treatment "Joan Pavel"
Sofia, Bulgaria, 1233
Germany
Vivantes Klinikum im Friedrichshain, Hemophilia Care Center for Children and Adults
Berlin, Germany, 10249
UKGM Uniklinikum Giessen & Marburg
Giessen, Germany, 35392
Harrison Clinical Research Deutschland
Munich, Germany, 80636
Japan
Nara Medical University Hospital
Nara, Japan, 630-8521
Tokyo Medical University Hospital
Tokyo, Japan, 160-0023
United Kingdom
Quintiles Drug Research Unit at Guy´s Hospital
London, United Kingdom, SE1 1YR
Manchester Haemophilia Comprehensive Care Centre, Manchester Royal Infirmary
Manchester, United Kingdom, M13 9WL
Sponsors and Collaborators
Baxalta now part of Shire
Baxter Innovations GmbH
Investigators
Study Director: BioScience Investigator, MD Baxter Healthcare Corporation
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Baxalta now part of Shire
ClinicalTrials.gov Identifier: NCT01599819     History of Changes
Other Study ID Numbers: 261101
2011-002011-28 ( EudraCT Number )
First Submitted: May 15, 2012
First Posted: May 16, 2012
Last Update Posted: October 23, 2017
Last Verified: September 2012

Additional relevant MeSH terms:
Hemophilia A
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Factor VIII
Coagulants